Halozyme Wins Dutch Injunction Against Merck and Expands Argenx Partnership
Halozyme Therapeutics, Inc. (HALO) secured a court injunction in the Netherlands that halts the manufacturing and sale of Merck’s subcutaneous cancer drug Keytruda SC across eight European nations. The legal ruling stems from an ongoing dispute concerning Halozyme's MDASE patent. Alongside the legal victory, Halozyme expanded its ENHANZE licensing collaboration with argenx, adding two exclusive targets to bring the total agreement to eight subcutaneous therapy targets.
The broadened deal with argenx ensures Halozyme will earn milestone payments and ongoing royalties as therapy development advances. Following the developments, financial analysts at JP Morgan raised their price target on Halozyme shares from $70 to $78. Shares of Halozyme were trading at 110.4 USD, up 0.53% for the session.
Both Halozyme and Merck are currently evaluating their options following the court decision. Market participants will be watching for Merck's legal response to the European block and tracking progress under the expanded ENHANZE alliance.
Key points
- A Dutch court issued an injunction forcing Merck to stop producing and selling Keytruda SC in eight European countries over Halozyme's MDASE patent.
- Halozyme expanded its ENHANZE partnership with argenx by adding two new exclusive targets, bringing the total program count to eight targets.
- Halozyme is set to receive milestone payments and royalties from argenx as development progresses on the subcutaneous therapies.
- JP Morgan increased its price target for Halozyme shares to $78 from $70 as both companies evaluate their next moves.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Why did Halozyme win a Dutch injunction against Merck?
Halozyme won a court injunction in the Netherlands against Merck over an MDASE patent dispute, blocking Merck from manufacturing and selling Keytruda SC in eight European countries.
How is Halozyme expanding its partnership with argenx?
Halozyme added two exclusive ENHANZE-enabled targets to its partnership with argenx, bringing the total to eight targets for subcutaneous therapy development and generating future milestones and royalties.
What is JP Morgan's new price target for Halozyme Therapeutics?
JP Morgan raised its price target for Halozyme Therapeutics stock from $70 to $78 following the legal and partnership updates.